0
Startups & Venture·October 23, 2026·1 min read

DeepSeek reportedly raises $15bn from Tencent and CATL ahead of IPO

Share

$15B into a single Chinese AI lab means national-scale balance sheets are now underwriting model development as strategic infrastructure. Anyone competing on foundation models without similar capital access should assume they’re playing a different game — and focus on domain, distribution, or data moats instead.

Startups & Venture

Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025

Pathos AI nearly doubling valuation to $3B in ~18 months on a $237M Series E is a clear vote that AI-native drug discovery—especially in oncology—is moving from story to pipeline. If you’re a traditional biotech, expect investors and partners to benchmark your discovery engine against AI-first peers on cycle time and hit quality, not just clinical endpoints.